In another study, with a second-generation allogeneic CAR, durable responses of 85% CR were reported in a subset of r/r T-ALL with a median follow-up time of 27 months (17/20 patients),22 and a recent phase I trial with sequential allogeneic CD7 CAR T cell therapy and haploidentical stem cell transplantation resulted in an estimated 1-year OS of 68%.23 The gene discussed is CD7; the disease is acute lymphoblastic leukemia.